Pertuzumab in metastatic breast cancer: Unanswered questions

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Capelan, Marta
Pugliano, Lina
de Azambuja, Evandro
Bozovic, Ivana
Saini, Kamal
Sotiriou, Christos
Loi, Sherene
Piccart-Gebhart, Martine

August 2012

BackgroundHuman epidermal growth factor receptor 2 (HER2) overexpression is detected in approximatel...

Trastuzumab in the treatment of breast cancer

Maximiano, Sofia
Magalhães, Paulo
Guerreiro, Mara Pereira
Morgado, Manuel

January 2016

Breast cancer (BC) is the most common cancer in women worldwide, and has an undeniable negative impa...

Regulatory Issues: EMA The EuropeanMedicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal

September 2016

Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. P...

Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer

Amit Rauthan
Palanki Satya Dattatreya
Manish Singhal
Ram Prabu
Siddharth Naik
Anil Kukreja

January 2015

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more aggressive subtype ...

Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.

Pérez-García, José Manuel
Gebhart, Geraldine
Borrego, Manuel Ruiz
Schmid, Peter
Marmé, Frederik
Prat, Aleix
Dalenc, Florence
Kerrou, Khaldoun
Colleoni, Marco
Braga, Sofía
Malfettone, Andrea
Sampayo-Cordero, Miguel
Cortés, Javier
Llombart-Cussac, Antonio

October 2022

This is a summary of a publication about the PHERGain study, which was published in The Lancet Oncol...

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

Moya-Horno I
Cortés J

May 2015

I Moya-Horno,1 J Cortés1,2 1Department of Medical Oncology, Instituto Oncológico Basel...

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Swain, Sandra M.
Miles, David
Kim, Sung-Bae
Im, Young-Hyuck
Im, Seock-Ah
Semiglazov, Vladimir
Ciruelos, Eva
Schneeweiss, Andreas
Loi, Sherene
Monturus, Estefania
Clark, Emma
Knott, Adam
Restuccia, Eleonora
Benyunes, Mark C.
Cortes, Javier]

April 2020

Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzuma...

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer : summary of the scientific assessment of the committee for medicinal products for human use

Boix-Perales, Hector
Borregaard, Jeanett
Jensen, Kristina Bech
Ersbøll, Jens
Galluzzo, Sara
Giuliani, Rosa
Ciceroni, Cinzia
Melchiorri, Daniela
Salmonson, Tomas
Bergh, Jonas
Schellens, Jan H
Pignatti, Francesco

July 2014

Pertuzumab is a recombinant humanized monoclonal antibody that specifically targets the extracellula...

The European Medicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

H. Boix-Perales
J. Borregaard
K.B. Jensen
J. Ersboll
S. Galluzzo
R. Giuliani
Cinzia Ciceroni
Daniela Melchiorri
T. Salmonson
J. Bergh
J.H. Schellens
F. Pignatti

January 2014

Pertuzumab is a recombinant humanized monoclonal antibody that specifically targets the extracellula...

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Saini, Kamal
Abdel Azim, Hatem Hamdy
Metzger-Filho, Otto
Loi, Sherene
Sotiriou, Christos
de Azambuja, Evandro
Piccart-Gebhart, Martine

October 2011

HER2-positive tumors comprise 15% to 20% of all breast cancers (BC) and are associated with worse cl...

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data

Jagosky M
Tan AR

June 2021

Megan Jagosky, Antoinette R Tan Department of Solid Tumor Oncology and Investigational Therapeutics,...

Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer

Ece Esin
Omur Berna Cakmak Oksuzoglu
Erkan Erdur
Ozgen Ahmet Yildirim
Guliz Zengin
Aysegul Ilhan
Ulku Arslan
Umut Demirci

April 2018

Introduction: With the development and widely use of HER2 targeted therapies, HER2 expressing metast...

which permits unrestricted noncommercial use, provided the original work is properly cited. Breast Cancer: Targets and Therapy 2012:4 65–73 Breast Cancer: Targets and Therapy Role of pertuzumab in the treatment of HER2-positive breast cancer

Michael Hubalek
Christine Brantner
Christian Marth
Brustgesundheitzentrum Tirol
Correspondence Michael Hubalek
Brustgesundheitzentrum Tirol

September 2016

Abstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising n...

Weighing the Options for Human Epidermal Growth Factor Receptor 2–Directed Therapy in Metastatic Breast Cancer

Nancy U. Lin

October 2016

Since the introduction of trastuzumab in the late 1990s, the treatment landscape for patients with m...

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Miles D.
Ciruelos E.
Schneeweiss A.
Puglisi F.
Peretz-Yablonski T.
Campone M.
Bondarenko I.
Nowecki Z.
Errihani H.
Paluch-Shimon S.
Wardley A.
Merot J. -L.
Trask P.
du Toit Y.
Pena-Murillo C.
Revelant V.
Klingbiel D.
Bachelot T.
Bouzid K.
Desmoulins I.
Coudert B.
Glogowska I.
Ciruelos Gil E.
Dalenc F.
Ricci F.
Dieras V.
Kaufman B.
Ferreira A.
Mano M.
Kalofonos H.
Andreetta C.
Montemurro F.
Barrett S.
Zhang Q.
Mavroudis D.
Matus J.
Villarreal Garza C.
Beato C.
Ismael G.
Hu X.
Abdel Azeem H.
Gaafar R.
Perrin C.
Kerbrat P.
Ettl J.
Paepke S.
Hitre E.
Lang I.
Trudeau M.
Verma S.
Li H.
Hoffmann O.
Aktas B.
Cariello A.
Cruciani G.
Tienghi A.
Tondini C.
Al-Twegieri T.
Loman N.
Laing R.
Brain E.
Fasching P.
Lux M.
Frassoldati A.
Aziz Z.
Salas J.
Streb J.
Krzemieniecki K.
Wronski A.
Garcia Garcia J.
Menjon Beltran S.
Cicin I.
Schmid P.
Gallagher C.
Turner N.
Tong Z.
Boer K.
Juhasz B.
Horvath Z.
Bianchini G.
Gianni L.
Curigliano G.
Juarez Ramiro A.
Susnjar S.
Matos E.
Sevillano E.
Garcia Estevez L.
Gokmen E.
Uslu R.
Wildiers H.
Schutz F.
Cruz M.
Bourgeois H.
von Schumann R.
Stemmer S.
Dominguez A.
Morales-Vasques F.
Wojtukiewicz M.
Trifunovic J.
Echarri Gonzalez M. J.
Illarramendi Manas J.
Martinez De Duenas E.
Voitko N.
Hicks J.
Waters S.
Barrett-Lee P.
Wheatley D.
De Boer R.
Cocquyt V.
Jerusalem G.
Barrios C.
Panasci L.
Mattson J.
Tanner M.
Gozy M.
Vasilopoulos G.
Papandreou C.
Revesz J.
Battelli N.
Benedetti G.
Latini L.
Gridelli C.
Lazaro Leon J.
Alarcon Company J.
Arance Fernandez A.
Barnadas Molins A.
Calvo Plaza I.
Bratos R.
Gonzalez Martin A.
Izarzugaza Peron Y.
Klint L.
Kovalev A.
McCarthy N.
Yeo B.
Kee D.
Thomson J.
White S.
Greil R.
Wang S.
Artignan X.
Juhasz-Boess I.
Rody A.
Ngan R.
Dourleshter F.
Goldberg H.
Doni L.
Di Costanzo F.
Ferrau F.
Drobniene M.
Aleknavicius E.
Rashid K.
Costa L.
de la Cruz Merino L.
Garcia Saenz J.
Lopez R.
Del Val Munoz O.
Ozyilkan O.
Azribi F.
Jaafar H.
Baird R.
Verrill M.
Beith J.
Petzer A.
Moreira de Andrade J.
Bernstein V.
Macpherson N.
Rayson D.
Saad Eldin I.
Achille M.
Augereau P.
Muller V.
Rasco A.
Evron E.
Katz D.
Berardi R.
Cascinu S.
De Censi A.
Gennari A.
El-Saghir N.
Ghosn M.
Oosterkamp H. M.
Van den Bosch J.
Kukulska M.
Kalinka E.
Alonso J.
Dalmau Portulas E.
Del Mar Gordon Santiago M.
Pelaez Fernandez I.
Aksoy S.
Altundag K.
Senol Coskun H.
Bozcuk H.
Shparyk Y.
Barraclough L.
Levitt N.
Panwar U.
Kelly S.
Rigg A.
Varughese M.
Castillo C.
Fein L.
Malik L.
Stuart-Harris R.
Singer C.
Stoeger H.
Samonigg H.
Feng J.
Cedeno M.
Ruohola J.
Berdah J. -F.
Goncalves A.
Orfeuvre H.
Grischke E. -M.
Simon E.
Wagner S.
Koumakis G.
Papazisis K.
Ben Baruch N.
Fried G.
Geffen D.
Karminsky N.
Peretz T.
Cavanna L.
Pedrazzioli P.
Grasso D.
Ruggeri E.
D'Auria G.
Moscetti L.
Juozaityte E.
Rodriguez Cid J.
Roerdink H.
Siddiqi N.
Passos Coelho J.
Arcediano Del Amo A.
Garcia Garre E.
Garcia Gonzalez M.
Garcia-Palomo Perez A.
Herenandez Perez C.
Lopez Alvarez P.
Lopez De Ceballos M. H.
Martinez Janez N.
Mele Olive M.
McAdam K.
Perren T.
Dunn G.
Humphreys A.
Taylor W.
Vera R.
Kaen L.
Andel J.
Steger G.
De Greve J.
Huizing M.
Hegg R.
Joy A.
Kuruvilla P.
Sehdev S.
Smiljanic S.
Kutner R.
Alexandre J.
Grosjean J.
Laplaige P.
Largillier R.
Maes P.
Martin P.
Pottier V.
Christensen B.
Khandan F.
Luck H. -J.
Zahm D. -M.
Fountzilas G.
Karavasilis V.
Safra T.
Inbar M.
Ryvo L.
Bonetti A.
Seles E.
Giacobino A.
Chavarri Guerra Y.
de Jongh F.
van der Velden A.
van Warmerdam L.
Vrijaldenhoven S.
Smorenburg C. H.
Cavero M.
Andres Conejero R.
Oltra Ferrando A.
Redondo Sanchez A.
Ribelles Entrena N.
Saura Grau S.
Vinas Vilaro G.
Bachmeier K.
Beresford M.
Butt M.
Joffe J.
Poole C.
Woodings P.
Chakraborti P.
Yordi G.
Woodward N.
Nobre A.
Luiz Amorim G.
Califaretti N.
Fox S.
Robidoux A.
Li E.
Li N.
Jiang J.
Soria T.
Padrik P.
Lahdenpera O.
Barletta H.
Dohollou N.
Genet D.
Prulhiere K.
Coeffic D.
Facchini T.
Vieillot S.
Catala S.
Teixeira L.
Hesse T.
Kuhn T.
Ober A.
Repp R.
Schroder W.
Pectasides D.
Bodoky G.
Kahan Z.
Jiveliouk I.
Rosengarten O.
Rossi V.
Alabiso O.
Perez Martinez M.
van de Wouw A. J.
Smok-Kalwat J.
Damasecno M.
Augusto I.
Sousa G.
Saadein A.
Abdelhafiez N.
Abulkhair O.
Anton Torres A.
Corbellas Aparicio M.
Llorente Domenech R.
Florian Jerico J.
Garcia Mata J.
Gil Raga M.
Galan Brotons A.
Llombart Cussac A.
Llorca Ferrandiz C.
Martinez Del Prado P.
Olier Garate C.
Rodriguez Sanchez C.
Sanchez Gomez R.
Santisteban Eslava M.
Soberino J.
Vidal Losada Garcia M.
Soto de Prado D.
Torrego Garcia J.
Vicente Rubio E.
Garcia M.
Murias Rosales A.
Granstam Bjorneklett H.
Narbe U.
Jafri M.
Rea D.
Newby J.
Jones A.
Westwell S.
Ring A.
Alonso I.
Rodriguez R.

January 2021

Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial establ...

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Capelan, Marta
Pugliano, Lina
de Azambuja, Evandro
Bozovic, Ivana
Saini, Kamal
Sotiriou, Christos
Loi, Sherene
Piccart-Gebhart, Martine

August 2012

BackgroundHuman epidermal growth factor receptor 2 (HER2) overexpression is detected in approximatel...

Trastuzumab in the treatment of breast cancer

Maximiano, Sofia
Magalhães, Paulo
Guerreiro, Mara Pereira
Morgado, Manuel

January 2016

Breast cancer (BC) is the most common cancer in women worldwide, and has an undeniable negative impa...

Regulatory Issues: EMA The EuropeanMedicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal

September 2016

Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. P...

Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer

Amit Rauthan
Palanki Satya Dattatreya
Manish Singhal
Ram Prabu
Siddharth Naik
Anil Kukreja

January 2015

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more aggressive subtype ...

Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.

Pérez-García, José Manuel
Gebhart, Geraldine
Borrego, Manuel Ruiz
Schmid, Peter
Marmé, Frederik
Prat, Aleix
Dalenc, Florence
Kerrou, Khaldoun
Colleoni, Marco
Braga, Sofía
Malfettone, Andrea
Sampayo-Cordero, Miguel
Cortés, Javier
Llombart-Cussac, Antonio

October 2022

This is a summary of a publication about the PHERGain study, which was published in The Lancet Oncol...

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

Moya-Horno I
Cortés J

May 2015

I Moya-Horno,1 J Cortés1,2 1Department of Medical Oncology, Instituto Oncológico Basel...

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Swain, Sandra M.
Miles, David
Kim, Sung-Bae
Im, Young-Hyuck
Im, Seock-Ah
Semiglazov, Vladimir
Ciruelos, Eva
Schneeweiss, Andreas
Loi, Sherene
Monturus, Estefania
Clark, Emma
Knott, Adam
Restuccia, Eleonora
Benyunes, Mark C.
Cortes, Javier]

April 2020

Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzuma...

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer : summary of the scientific assessment of the committee for medicinal products for human use

Boix-Perales, Hector
Borregaard, Jeanett
Jensen, Kristina Bech
Ersbøll, Jens
Galluzzo, Sara
Giuliani, Rosa
Ciceroni, Cinzia
Melchiorri, Daniela
Salmonson, Tomas
Bergh, Jonas
Schellens, Jan H
Pignatti, Francesco

July 2014

Pertuzumab is a recombinant humanized monoclonal antibody that specifically targets the extracellula...

The European Medicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

H. Boix-Perales
J. Borregaard
K.B. Jensen
J. Ersboll
S. Galluzzo
R. Giuliani
Cinzia Ciceroni
Daniela Melchiorri
T. Salmonson
J. Bergh
J.H. Schellens
F. Pignatti

January 2014

Pertuzumab is a recombinant humanized monoclonal antibody that specifically targets the extracellula...

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Saini, Kamal
Abdel Azim, Hatem Hamdy
Metzger-Filho, Otto
Loi, Sherene
Sotiriou, Christos
de Azambuja, Evandro
Piccart-Gebhart, Martine

October 2011

HER2-positive tumors comprise 15% to 20% of all breast cancers (BC) and are associated with worse cl...

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data

Jagosky M
Tan AR

June 2021

Megan Jagosky, Antoinette R Tan Department of Solid Tumor Oncology and Investigational Therapeutics,...

Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer

Ece Esin
Omur Berna Cakmak Oksuzoglu
Erkan Erdur
Ozgen Ahmet Yildirim
Guliz Zengin
Aysegul Ilhan
Ulku Arslan
Umut Demirci

April 2018

Introduction: With the development and widely use of HER2 targeted therapies, HER2 expressing metast...

which permits unrestricted noncommercial use, provided the original work is properly cited. Breast Cancer: Targets and Therapy 2012:4 65–73 Breast Cancer: Targets and Therapy Role of pertuzumab in the treatment of HER2-positive breast cancer

Michael Hubalek
Christine Brantner
Christian Marth
Brustgesundheitzentrum Tirol
Correspondence Michael Hubalek
Brustgesundheitzentrum Tirol

September 2016

Abstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising n...

Weighing the Options for Human Epidermal Growth Factor Receptor 2–Directed Therapy in Metastatic Breast Cancer

Nancy U. Lin

October 2016

Since the introduction of trastuzumab in the late 1990s, the treatment landscape for patients with m...

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Miles D.
Ciruelos E.
Schneeweiss A.
Puglisi F.
Peretz-Yablonski T.
Campone M.
Bondarenko I.
Nowecki Z.
Errihani H.
Paluch-Shimon S.
Wardley A.
Merot J. -L.
Trask P.
du Toit Y.
Pena-Murillo C.
Revelant V.
Klingbiel D.
Bachelot T.
Bouzid K.
Desmoulins I.
Coudert B.
Glogowska I.
Ciruelos Gil E.
Dalenc F.
Ricci F.
Dieras V.
Kaufman B.
Ferreira A.
Mano M.
Kalofonos H.
Andreetta C.
Montemurro F.
Barrett S.
Zhang Q.
Mavroudis D.
Matus J.
Villarreal Garza C.
Beato C.
Ismael G.
Hu X.
Abdel Azeem H.
Gaafar R.
Perrin C.
Kerbrat P.
Ettl J.
Paepke S.
Hitre E.
Lang I.
Trudeau M.
Verma S.
Li H.
Hoffmann O.
Aktas B.
Cariello A.
Cruciani G.
Tienghi A.
Tondini C.
Al-Twegieri T.
Loman N.
Laing R.
Brain E.
Fasching P.
Lux M.
Frassoldati A.
Aziz Z.
Salas J.
Streb J.
Krzemieniecki K.
Wronski A.
Garcia Garcia J.
Menjon Beltran S.
Cicin I.
Schmid P.
Gallagher C.
Turner N.
Tong Z.
Boer K.
Juhasz B.
Horvath Z.
Bianchini G.
Gianni L.
Curigliano G.
Juarez Ramiro A.
Susnjar S.
Matos E.
Sevillano E.
Garcia Estevez L.
Gokmen E.
Uslu R.
Wildiers H.
Schutz F.
Cruz M.
Bourgeois H.
von Schumann R.
Stemmer S.
Dominguez A.
Morales-Vasques F.
Wojtukiewicz M.
Trifunovic J.
Echarri Gonzalez M. J.
Illarramendi Manas J.
Martinez De Duenas E.
Voitko N.
Hicks J.
Waters S.
Barrett-Lee P.
Wheatley D.
De Boer R.
Cocquyt V.
Jerusalem G.
Barrios C.
Panasci L.
Mattson J.
Tanner M.
Gozy M.
Vasilopoulos G.
Papandreou C.
Revesz J.
Battelli N.
Benedetti G.
Latini L.
Gridelli C.
Lazaro Leon J.
Alarcon Company J.
Arance Fernandez A.
Barnadas Molins A.
Calvo Plaza I.
Bratos R.
Gonzalez Martin A.
Izarzugaza Peron Y.
Klint L.
Kovalev A.
McCarthy N.
Yeo B.
Kee D.
Thomson J.
White S.
Greil R.
Wang S.
Artignan X.
Juhasz-Boess I.
Rody A.
Ngan R.
Dourleshter F.
Goldberg H.
Doni L.
Di Costanzo F.
Ferrau F.
Drobniene M.
Aleknavicius E.
Rashid K.
Costa L.
de la Cruz Merino L.
Garcia Saenz J.
Lopez R.
Del Val Munoz O.
Ozyilkan O.
Azribi F.
Jaafar H.
Baird R.
Verrill M.
Beith J.
Petzer A.
Moreira de Andrade J.
Bernstein V.
Macpherson N.
Rayson D.
Saad Eldin I.
Achille M.
Augereau P.
Muller V.
Rasco A.
Evron E.
Katz D.
Berardi R.
Cascinu S.
De Censi A.
Gennari A.
El-Saghir N.
Ghosn M.
Oosterkamp H. M.
Van den Bosch J.
Kukulska M.
Kalinka E.
Alonso J.
Dalmau Portulas E.
Del Mar Gordon Santiago M.
Pelaez Fernandez I.
Aksoy S.
Altundag K.
Senol Coskun H.
Bozcuk H.
Shparyk Y.
Barraclough L.
Levitt N.
Panwar U.
Kelly S.
Rigg A.
Varughese M.
Castillo C.
Fein L.
Malik L.
Stuart-Harris R.
Singer C.
Stoeger H.
Samonigg H.
Feng J.
Cedeno M.
Ruohola J.
Berdah J. -F.
Goncalves A.
Orfeuvre H.
Grischke E. -M.
Simon E.
Wagner S.
Koumakis G.
Papazisis K.
Ben Baruch N.
Fried G.
Geffen D.
Karminsky N.
Peretz T.
Cavanna L.
Pedrazzioli P.
Grasso D.
Ruggeri E.
D'Auria G.
Moscetti L.
Juozaityte E.
Rodriguez Cid J.
Roerdink H.
Siddiqi N.
Passos Coelho J.
Arcediano Del Amo A.
Garcia Garre E.
Garcia Gonzalez M.
Garcia-Palomo Perez A.
Herenandez Perez C.
Lopez Alvarez P.
Lopez De Ceballos M. H.
Martinez Janez N.
Mele Olive M.
McAdam K.
Perren T.
Dunn G.
Humphreys A.
Taylor W.
Vera R.
Kaen L.
Andel J.
Steger G.
De Greve J.
Huizing M.
Hegg R.
Joy A.
Kuruvilla P.
Sehdev S.
Smiljanic S.
Kutner R.
Alexandre J.
Grosjean J.
Laplaige P.
Largillier R.
Maes P.
Martin P.
Pottier V.
Christensen B.
Khandan F.
Luck H. -J.
Zahm D. -M.
Fountzilas G.
Karavasilis V.
Safra T.
Inbar M.
Ryvo L.
Bonetti A.
Seles E.
Giacobino A.
Chavarri Guerra Y.
de Jongh F.
van der Velden A.
van Warmerdam L.
Vrijaldenhoven S.
Smorenburg C. H.
Cavero M.
Andres Conejero R.
Oltra Ferrando A.
Redondo Sanchez A.
Ribelles Entrena N.
Saura Grau S.
Vinas Vilaro G.
Bachmeier K.
Beresford M.
Butt M.
Joffe J.
Poole C.
Woodings P.
Chakraborti P.
Yordi G.
Woodward N.
Nobre A.
Luiz Amorim G.
Califaretti N.
Fox S.
Robidoux A.
Li E.
Li N.
Jiang J.
Soria T.
Padrik P.
Lahdenpera O.
Barletta H.
Dohollou N.
Genet D.
Prulhiere K.
Coeffic D.
Facchini T.
Vieillot S.
Catala S.
Teixeira L.
Hesse T.
Kuhn T.
Ober A.
Repp R.
Schroder W.
Pectasides D.
Bodoky G.
Kahan Z.
Jiveliouk I.
Rosengarten O.
Rossi V.
Alabiso O.
Perez Martinez M.
van de Wouw A. J.
Smok-Kalwat J.
Damasecno M.
Augusto I.
Sousa G.
Saadein A.
Abdelhafiez N.
Abulkhair O.
Anton Torres A.
Corbellas Aparicio M.
Llorente Domenech R.
Florian Jerico J.
Garcia Mata J.
Gil Raga M.
Galan Brotons A.
Llombart Cussac A.
Llorca Ferrandiz C.
Martinez Del Prado P.
Olier Garate C.
Rodriguez Sanchez C.
Sanchez Gomez R.
Santisteban Eslava M.
Soberino J.
Vidal Losada Garcia M.
Soto de Prado D.
Torrego Garcia J.
Vicente Rubio E.
Garcia M.
Murias Rosales A.
Granstam Bjorneklett H.
Narbe U.
Jafri M.
Rea D.
Newby J.
Jones A.
Westwell S.
Ring A.
Alonso I.
Rodriguez R.

January 2021

Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial establ...

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Capelan, Marta
Pugliano, Lina
de Azambuja, Evandro
Bozovic, Ivana
Saini, Kamal
Sotiriou, Christos
Loi, Sherene
Piccart-Gebhart, Martine

August 2012

BackgroundHuman epidermal growth factor receptor 2 (HER2) overexpression is detected in approximatel...

Trastuzumab in the treatment of breast cancer

Maximiano, Sofia
Magalhães, Paulo
Guerreiro, Mara Pereira
Morgado, Manuel

January 2016

Breast cancer (BC) is the most common cancer in women worldwide, and has an undeniable negative impa...

Regulatory Issues: EMA The EuropeanMedicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal

September 2016

Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. P...

Pertuzumab in metastatic breast cancer: Unanswered questions

Abstract

Extracted data

Pertuzumab in metastatic breast cancer: Unanswered questions

Abstract

Extracted data

Related items

Related items